Vertex's triple combo cystic-fibrosis drug meets main late-stage study goals

Vertex Pharmaceuticals' (VRTX.O), opens new tab experimental cystic-fibrosis treatment met all of its main goals in a late-stage study when tested in patients aged 12 years and older, the company said on Monday.